Shots:

• AbCellera to receive technology access fee- funding- milestones- and royalties on sales of products. Novartis to get rights to license AbCellera’s technology for its 10 unknown targets
• Additionally- AbCellera collaborated with Pfizer- Teva and GSK on 5 Jan-2017- 13 Jun-2017- and on 12 Sept-2017 respectively for its Ab-based technology targeting membrane proteins and collaborated with Autolus Therapeutics & Denali Therapeutics for neurodegenerative disorders
• AbCellera’s technology is single cell Ab-based discovery platform used for targeting GPCRs and ion channels with the identification of mAbs from Single B cells in multiple therapy areas

Ref: AbCellera | Image: Business Wire